Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tumor mutation burden and JARID2 gene alteration are associated with short disease-free survival in locally advanced triple-negative breast cancer

1 Sept 2020

Abstract excerpt

Background: In locally advanced triple-negative breast cancer (TNBC), patients who did not achieve pathologic complete response (non-pCR) after neoadjuvant chemotherapy develop rapid tumor metastasis. Tumor mutation burden (TMB) is a potential biomarker of cancer therapy, though whether it is applicable to TNBC is still unclear. Methods: A total of 14 non-pCR TNBC patients were enrolled, and tissue samples from...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Genetic factors in colorectal cancer
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33145271
DOI: 10.21037/atm-20-3773

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tumor mutation burden and JARID2 gene alteration are associated with short disease-free survival in locally advanced triple-negative breast cancerPMID 33145271Read ↗

Next-Generation Sequencing and Triple-Negative Breast Cancer: Insights and Applications.Semantic proximity Read ↗

MIR4435-2HG: A Novel Biomarker for Triple-Negative Breast Cancer Diagnosis and Prognosis, Driving Tumor Progression through EMT by JNK/c-Jun and p38 MAPK Signaling Pathway ActivationSemantic proximity Read ↗

Identification of biomarker associated with Trop2 in breast cancer: implication for targeted therapySemantic proximity Read ↗

DNA damage response as a prognostic indicator in metastatic breast cancer via mutational analysisSemantic proximity Read ↗

The oncogenic kinase NEK2 regulates an RBFOX2-dependent pro-mesenchymal splicing program in triple-negative breast cancer cellsSemantic proximity Read ↗

MYBL2-induced PITPNA-AS1 upregulates SIK2 to exert oncogenic function in triple-negative breast cancer through miR-520d-5p and DDX54Semantic proximity Read ↗

Kinome-Wide siRNA Screening Identifies DYRK1B as a Potential Therapeutic Target for Triple-Negative Breast Cancer CellsSemantic proximity Read ↗

Clinical genomic profiling to identify actionable alterations for very early relapsed triple-negative breast cancer patients in the Chinese population.Semantic proximity Read ↗

Comparison of mutational profiles between triple-negative and hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancers in T2N0-1M0 stage: Implications of TP53 and PIK3CA mutations in Korean early-stage breast cancers.Semantic proximity Read ↗

Genomic Characterization of de novo Metastatic Breast Cancer.Semantic proximity Read ↗

MDN1 Mutation Is Associated With High Tumor Mutation Burden and Unfavorable Prognosis in Breast CancerSemantic proximity Read ↗

Multifaceted roles of long non-coding RNAs in triple-negative breast cancer: biology and clinical applications.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.